Dear Doctor Letter (Rote-Hand-Brief) on ▼Increlex® (Mecasermin): risk of benign and malignant neoplasia
2019.12.02
Active substance: Mecasermin
Ipsen Pharma, in agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM), would like to inform you of Cases of benign and malignant neoplasms that have been observed among children and adolescents who received treatment with mecasermin in the post-marketing setting.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN